Buy Cagrilintide 5mg

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk for once-weekly subcutaneous dosing. Amylin is a peptide co-secreted with insulin from pancreatic beta cells that slows gastric emptying, reduces glucagon secretion, and signals satiety to the brain. Cagrilintide recapitulates these effects with a half-life that supports weekly dosing.

▸The Amylin Mechanism

Amylin works through a distinct receptor system (calcitonin receptor/RAMP complexes) that is entirely separate from GLP-1 receptors. This means cagrilintide adds complementary appetite and metabolic effects without receptor cross-talk or competition. When combined with semaglutide (as CagriSema), the two compounds produce synergistic weight loss beyond either alone.

▸CagriSema Clinical Evidence

The Phase III REDEFINE 1 trial of CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg once weekly) demonstrated 22.7% body weight reduction at 68 weeks versus 16.1% for semaglutide alone — a 42% improvement attributable solely to the addition of cagrilintide. This validated amylin agonism as a meaningful complementary mechanism.

▸Standalone Cagrilintide

As a standalone, cagrilintide at 4.5mg/week produced approximately 10.8% body weight reduction in Phase II — less than semaglutide alone, but with complementary mechanisms that stack additively when combined.